NL-OMON28532尚未招募不适用
Botulinum neurotoxin as new treatment modality in jerky psychogenic movement disorders: A randomized controlled trial.
Academic Medical CentreMeibergdreef 91105 AZ Amsterdam0 个研究点目标入组 54 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 54
研究概览
简要总结
/A
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Eligible patients for the study have at least one consistent type of jerk of psychogenic origin. Two movement disorder specialists have to agree on the diagnosis based on clinical characteristics and on additional investigations if considered necessary. The diagnosis of psychogenic jerks needs to have a definite” or probable” level of certainty for psychogenic movement disorders. To be included, patients need to experience to be significantly impaired in daily functioning due to one specific jerk. The jerk of interest needs to be performed by a muscle or muscles amendable to injection and may be simple or complex if only treatment with BoNT is considered possible. No change in medication in the month prior to participation is allowed.
排除标准
- •1. Age < 18 years or > 80 years;
- •2. Psychogenic jerk of interest present for < 1 year;
研究者
相似试验
招募中
不适用
botulinum in childhood strabismusEye DiseasesSurgeryPaediatricschildhood strabismusPACTR201508001241218250
尚未招募
不适用
Botulinum Neurotoxin (BoNT) as new treatment for functional (psychogenic) jerky movementdisorders.Botulinum neurotoxin (BoNT) has emerged as a useful therapy for several movement disorders associated with muscle overactivity such as dystonia and jerky movement disorders. At least 2–9% of patients seen in movement disorder clinics suffer from movement disorders with a psychogenic origin and a substantial part of them has jerks. These psychogenic jerky movement disorders cannot be accounted for by a known neurologic syndrome.NL-OMON26050Academic Medical Center University of AmsterdamPO-box: 226601100 DD AmsterdamTel: 0031 (0)20 566911154
进行中（未招募）
不适用
Behandling med botulinumtoxin vid neurogen blåsfunktionsstörningThe trial addresses patients with severe symptoms of neurogenic detrusor overactivity (urgency and/or urge incontinence). Eligible are those patients who have failed conservative treatment such as behavioral techniques, physiotherapy, intermittent catheterisation or pharmacotherapy.EUCTR2005-003068-47-SERegion Skåne, Universitetssjukhuset i Lund, Urologiska kliniken40
已完成
2 期
Botulinum toxin as a new treatment modality for jerky psychogenic movement disorders: a monocenter randomized controlled trialfunctional movement disorder10028037conversion disorderNL-OMON34213Academisch Medisch Centrum50
已完成
4 期
Effect of Botulinum Toxin to Hallux Valgus in Addition to Total Contact InsoleHallux ValgusNCT01501500Chang Gung Memorial Hospital25